The E2F4 transcriptional repressor is a key mechanistic regulator of colon cancer resistance to irinotecan (CPT-11)

Junichi Matsubara, Yong Fuga Li, Sanjay Koul, Junko Mukohyama, Luis E. Valencia Salazar, Taichi Isobe, Dalong Qian, Michael F. Clarke, Debashis Sahoo, Russ B. Altman, Piero DalerbabioRxiv 2025 · DOI

TL;DR

Colorectal cancer (CRC) cells, particularly cancer stem cells (CSCs), often resist chemotherapy like irinotecan. This study identifies E2F4, a component of the DREAM transcriptional repressor complex, as a key player in this resistance. Suppressing E2F4 significantly enhances irinotecan's effectiveness, suggesting E2F4 as a potential therapeutic target to overcome chemoresistance.

What Problem Does This Paper Address?

Chemotherapy, including irinotecan (CPT-11), is a cornerstone for treating metastatic colorectal cancer (CRC). However, its efficacy is limited, with a significant portion of patients showing resistance, particularly those with cancer stem cell (CSC) populations. CSCs are a subset of cancer cells with stem-like properties, including self-renewal and differentiation, and are thought to drive tumor recurrence and resistance to therapy. While CSCs are known to be more resistant to chemotherapy, the precise molecular mechanisms underlying this resistance, especially to irinotecan, remain incompletely understood. This paper aims to elucidate these mechanisms by identifying transcriptional regulators that are preferentially activated in CSCs upon irinotecan treatment and investigating their role in drug resistance.

Methods

The researchers employed a multi-pronged approach:

  • Fluorescence-Activated Cell Sorting (FACS): They isolated two distinct populations of CRC cells from patient-derived xenograft (PDX) models: "bottom-of-the-crypt" cells (EpCAM+/CD44+/CD166+), enriched in CSCs, and "top-of-the-crypt" cells (EpCAM+/CD44neg/CD166neg), depleted of CSCs. This was done both before and after irinotecan treatment.
  • Gene Expression Profiling (Microarrays and RNA-seq): They analyzed the transcriptomes of these sorted cell populations to identify genes that were differentially expressed in response to irinotecan.
  • Transcription Factor Target Gene (TFTG) Enrichment Analysis: This bioinformatics approach was used to identify transcription factors whose activity was preferentially altered in CSCs upon irinotecan treatment, based on changes in their target gene expression.
  • Short Hairpin RNA (shRNA) Knockdown: To investigate the functional role of identified regulators, they used shRNAs to selectively reduce the expression of E2F4 in CRC cells.
  • In Vivo Studies: They tested the effect of E2F4 knockdown on tumor growth and response to irinotecan in mouse models (PDX).
  • Apoptosis Assays (Immunofluorescence): They quantified cell death in tumors to assess the impact of E2F4 knockdown on irinotecan's cytotoxic effects.
  • Extreme Limiting Dilution Analysis (ELDA): This method was used to evaluate the frequency of tumor-initiating cells after E2F4 knockdown.
  • Western Blotting and RT-qPCR: These techniques were used to confirm the efficiency of E2F4 knockdown at both the protein and mRNA levels.

Datasets

  • The Cancer Genome Atlas (TCGA): COAD (Colon Adenocarcinoma) and READ (Rectal Adenocarcinoma) datasets were used to compare E2F4 and TFDP1 mRNA expression levels between normal colon tissues and primary CRCs.
  • Mouse Colon Epithelium RNA-seq: Data from purified mouse colon epithelial cell populations (top-of-the-crypt, goblet cells, stem/progenitor cells) were used to study E2f4 and Tfdp1 expression across different cell lineages.
  • Gene Expression Omnibus (GEO) Repository: The full microarray dataset generated in this study is publicly available under accession number GSE213103.

Key Insights and Ideas

  • CSCs are intrinsically more resistant to irinotecan: The study confirmed that CSC-enriched populations (bottom-of-the-crypt) are significantly less susceptible to irinotecan-induced apoptosis compared to non-tumorigenic cells (top-of-the-crypt).
  • E2F4 and the DREAM complex are activated in CSCs by irinotecan: The TFTG analysis pinpointed E2F4 and its partner TFDP1, components of the DREAM transcriptional repression complex, as being preferentially activated in CSCs upon irinotecan treatment. This suggests a specific adaptive response in CSCs to chemotherapy.
  • E2F4 is a critical regulator of irinotecan resistance: Knocking down E2F4 expression in CRC cells dramatically sensitized them to irinotecan, both in terms of increased apoptosis and reduced tumor growth in vivo. This highlights E2F4's direct role in mediating resistance.
  • E2F4's role is not in proliferation but in survival: Interestingly, E2F4 knockdown did not affect the basal tumorigenic capacity or organoid-forming ability of CRC cells, suggesting its primary role in resistance is not by promoting proliferation but by enabling survival under chemotherapy stress.
  • E2F4 and DREAM complex as potential therapeutic targets: The findings strongly advocate for targeting E2F4 or the DREAM complex to enhance the efficacy of irinotecan therapy in CRC patients.

Key Results

  • Irinotecan treatment led to preferential activation of E2F4 and TFDP1 in CSC-enriched (EpCAM+/CD44+/CD166+) CRC cells compared to non-tumorigenic (EpCAM+/CD44neg/CD166neg) cells.
  • E2F4 and TFDP1 mRNA levels were higher in human CRCs compared to normal colon tissues and in stem/progenitor cell populations of mouse colonic epithelium.
  • Knockdown of E2F4 using shRNA constructs significantly increased the percentage of apoptotic cancer cells in tumors treated with irinotecan (from 3.8% to 12.9-14.8%).
  • E2F4 knockdown led to a substantial increase in drug sensitivity to irinotecan in three independent PDX models, resulting in profound reductions in average tumor volumes and growth rates, and in some cases, objective tumor responses.
  • E2F4 knockdown did not reduce the frequency of organoid-initiating cells (in vitro) or tumor-initiating cells (in vivo).

Limitations and Future Work

  • Biological Reason for Association: The study acknowledges that the precise biological reason for the association between E2F4 activation and irinotecan resistance remains unknown.
  • Translational Applications: The authors suggest that pharmacological manipulation of the DREAM complex, potentially through inhibitors of DYRK1A (which phosphorylates LIN52, a component of DREAM), could be a therapeutic strategy. Further pre-clinical studies are advocated to test DYRK1A inhibitors as chemo-sensitizers.
  • Broad Applicability: Given that irinotecan and its derivatives are widely used for various cancers and E2F4 and the DREAM complex are ubiquitously expressed, the findings have potential implications for improving chemotherapy efficacy across a broad spectrum of clinical settings and patient populations.

Summary updated

Abstract

Our data identified E2F4 and the DREAM repressor complex as critical regulators of human CRC resistance to <i>irinotecan</i>, and as candidate targets for the development of chemo-sensitizing agents.
BibTeX
@misc{matsubara2025e,
  author = {Junichi Matsubara and Yong Fuga Li and Sanjay Koul and Junko Mukohyama and Luis E. Valencia Salazar and Taichi Isobe and Dalong Qian and Michael F. Clarke and Debashis Sahoo and Russ B. Altman and Piero Dalerba},
  title = {{The E2F4 transcriptional repressor is a key mechanistic regulator of colon cancer resistance to <i>irinotecan</i> (CPT-11)}},
  year = {2025},
  doi = {10.1101/2025.01.22.633435},
  howpublished = {bioRxiv},
}
Figure